Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
5(71.4%)
Phase 2
2(28.6%)
7Total
N/A(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT06403631Completed

Supporting Mental Health in Daily Life After the Diagnosis of Multiple Sclerosis

Role: collaborator

NCT07114809Not ApplicableRecruiting

Impact of Anodal tDCS and Virtual Reality on Cognitive Dysfunction in Patients With Multiple Sclerosis

Role: collaborator

NCT05937802Not ApplicableUnknown

Osmotin Plant Protein for Progressive Multiple Sclerosis

Role: collaborator

NCT02339675Not ApplicableCompleted

Psychometric Properties Upper Limb Function Measures Multiple Sclerosis

Role: collaborator

NCT04027491Not ApplicableUnknown

Virtual Reality for Upper Limb Rehabilitation in Multiple Sclerosis

Role: collaborator

NCT00270816Phase 2Completed

Interferon ß-1b Treatment by Cyclical Administration

Role: collaborator

NCT02339688Not ApplicableCompleted

Psychometric Properties Mobility Measures MS

Role: collaborator

NCT00202410Phase 2Completed

Efficacy of Anti-Tubercular Vaccination in Multiple Sclerosis

Role: collaborator

All 8 trials loaded